Centessa Pharmaceuticals Plc SEC Filings

Centessa Pharmaceuticals (NASDAQ: CNTA) Form 4 shows General Counsel Iqbal J. Hussain exercised 12,000 stock options at $5.84 and immediately sold the same number of ordinary shares at a weighted-average $14.02 on 06/24/2025 under a Rule 10b5-1 plan.

Post-transaction, Hussain’s direct ownership declined by ~10% to 105,386 shares; he also holds 5,500 shares indirectly and 291,559 unexercised options.

• Gross sale proceeds ≈ $168.2 K.
• Sale represents >5% of insider’s pre-sale direct holdings, meeting materiality threshold.
• No impact on share count or dilution.

Insider selling by a senior legal officer can be viewed as a potential sentiment headwind, though execution under a pre-arranged 10b5-1 plan mitigates timing concerns.

Centessa (NASDAQ:CNTA) filed a Form 4 showing that President, Orexin Program Mario Alberto Accardi exercised options for 15,000 ordinary shares at $3.85 and immediately sold the same 15,000 shares at $14.00 on 06/24/2025 under a Rule 10b5-1 plan.

The transaction generated roughly $210 k in gross proceeds and reduced his direct holdings by 6.5% to 216,485 shares; he still holds 15,300 vested options. Because the sale exceeds 5% of his prior stake, it meets materiality thresholds for insider activity that investors track for sentiment shifts.

Centessa Pharmaceuticals (NASDAQ: CNTA) submitted a Form 144 notice covering the proposed sale of 10,000 common shares—approximately $140,000 in aggregate market value—through UBS Financial Services on or around 26 June 2025. The filing lists 133,618,774 shares outstanding, so the planned sale represents less than 0.01 % of the float.

The same account holder reported three earlier open‐market sales during the past three months: 10,000 shares on 25 March 2025 for $163,386, 11,742 shares on 25 April 2025 for $159,857, and 10,000 shares on 27 May 2025 for $128,225. Combined with the new notice, gross proceeds from the four transactions total roughly $591,000. No additional financial statements, risk factors, or business updates were provided in this routine disclosure.

A Form 144 filing from Centessa Pharmaceuticals indicates a proposed sale of 15,000 shares of common stock through UBS Financial Services. The shares have an aggregate market value of $210,000, with the sale planned for June 24, 2025 on the Nasdaq exchange.

The securities were acquired through the exercise of stock options from the issuer on June 24, 2025, with payment made in cash. The total outstanding shares of the company are 133,618,774.

Key details:

• Share price implied by filing: $14.00 per share
• No other securities sales reported by the seller in the past 3 months
• Transaction represents approximately 0.011% of total outstanding shares

Director Arjun Goyal of Centessa Pharmaceuticals was granted 40,000 stock options on June 20, 2025. The options have the following key terms:

• Exercise price set at $12.43 per share
• Expiration date of June 20, 2035
• Vesting occurs at earlier of: - First anniversary of grant date - Next annual shareholder meeting
• Options convert to ordinary shares (which may be represented as American Depositary Shares)
• Vesting conditional on continued service as director

This Form 4 filing, signed by attorney-in-fact Iqbal Hussain, represents a standard director compensation equity grant, suggesting continued commitment to aligning director interests with shareholders through long-term equity incentives.

Form 4 filing reveals that Mary Lynne Hedley, Director at Centessa Pharmaceuticals, was granted 40,000 share options on June 20, 2025. The stock options have an exercise price of $12.43 per share and will expire on June 20, 2035.

Key details of the option grant:

• Vesting occurs at the earlier of: (1) first anniversary of grant date or (2) next annual shareholder meeting
• Vesting is contingent on continued service as director
• Options are convertible into ordinary shares, which may be represented as American Depositary Shares (1:1 ratio)
• Direct ownership form reported

This grant appears to be part of the company's director compensation program. No other securities transactions were reported in this filing.

Form 4 filing reveals that Samarth Kulkarni, Director at Centessa Pharmaceuticals, received a stock option grant on June 20, 2025. Key details:

• Granted 40,000 stock options to purchase ordinary shares at an exercise price of $12.43 per share
• Options will vest in full at the earlier of: - First anniversary of grant date - Next annual shareholder meeting
• Options expire on June 20, 2035
• Vesting conditional on continued service as director
• Ordinary shares may be represented by American Depositary Shares (ADS), with each ADS representing one ordinary share

This equity compensation grant aligns with standard director compensation practices and aims to align the director's interests with shareholders. The filing was signed by Iqbal Hussain as attorney-in-fact on June 24, 2025.

Centessa Pharmaceuticals director Carol Stuckley received a stock option grant on June 20, 2025. The derivative securities transaction details include:

• Granted 40,000 share options to purchase ordinary shares
• Exercise price set at $12.43 per share
• Options expire on June 20, 2035
• Vesting occurs at earlier of:
  • First anniversary of grant date
  • Next annual shareholder meeting

The options are subject to continued service as director through the vesting date. Each ordinary share may be represented by one American Depositary Share (ADS). The transaction was reported via Form 4 filing with attorney-in-fact signature dated June 24, 2025.